Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

Telomir seeks FDA approval for Telomir-1 to treat breast cancer

 April 1, 2026

Pharmaceutical Business Review

The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment.

RegulatoryOncologyRead full story

Post navigation

FDA points to liver injury with Amgen’s Tavneos →
← Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com